Boyce Sarah 4

What Happened
Sarah Boyce, a director of Atrium Therapeutics, received a derivative award on February 27, 2026 covering 20,000 shares. The Form 4 reports the acquisition at $0.00 (i.e., a grant of options/awards rather than a cash purchase). No immediate cash value or exercise price is listed on the reported transaction.

Key Details

• Transaction date: 2026-02-27 (Form 4 filed 2026-03-02). No late filing flag indicated.
• Transaction type: Award/Grant of a derivative security (options) for 20,000 shares; acquisition price reported as $0.00.
• Vesting: Shares underlying the options vest in equal monthly installments over three years, subject to continuous service (footnote).
• Shares owned after transaction: Not specified in the provided filing.
• No 10b5-1 plan, tax withholding, or immediate sale reported in this filing.

Context
This was a standard equity compensation grant to a board member rather than an open-market purchase or sale. Such awards are commonly used for long-term incentive pay and do not, by themselves, indicate buying or selling sentiment. The vesting schedule means the shares/options become exercisable incrementally over three years, contingent on continued service.